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Edited by Veli-Pekka LehtoAbstract Leptin is 16 kDa adipokine that links nutritional status
with neuroendocrine and immune functions. Initially thought to be
a satiety factor that regulates body weight by inhibiting food in-
take and stimulating energy expenditure, leptin is a pleiotropic
hormone whose multiple eﬀects include regulation of endocrine
function, reproduction, and immunity. Leptin can be considered
as a pro-inﬂammatory cytokine that belongs to the family of
long-chain helical cytokines and has structural similarity with
interleukin-6, prolactin, growth hormone, IL-12, IL-15, granulo-
cyte colony-stimulating factor and oncostatin M. Because of its
dual nature as a hormone and cytokine, leptin links the neuroendo-
crine and the immune system. The role of leptin in the modulation
of immune response and inﬂammation has recently become
increasingly evident. The increase in leptin production that occurs
during infection and inﬂammation strongly suggests that leptin is a
part of the cytokine network which governs the inﬂammatory-im-
mune response and the host defense mechanisms. Leptin plays an
important role in inﬂammatory processes involving T cells and
has been reported tomodulate T-helper cells activity in the cellular
immune response. Several studies have implicated leptin in the
pathogenesis of autoimmune inﬂammatory conditions, such as
experimental autoimmune encephalomyelitis, type 1 diabetes,
rheumatoid arthritis, and intestinal inﬂammation. Very recently,
a key role for leptin in osteoarthritis has been demonstrated: leptin
indeed exhibits, in concert with other pro-inﬂammatory cytokines,
a detrimental eﬀect on articular cartilage by promoting nitric
oxide synthesis in chondrocytes. Here, we review the recent ad-
vances regarding leptin biology with a special focus on those ac-
tions relevant to the role of leptin in the pathophysiology of
inﬂammatory processes and immune responses.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Until recently, fat was considered to serve prevalently as the
triglyceride reservoir of the body and was relegated to a pas-*Corresponding author. Fax: +34 981 951068.
E-mail address: gualillo@usc.es (O. Gualillo).
0014-5793/$22.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.11.024sive endocrine role. The fact that adipose tissue was identiﬁed
as the major site for metabolism of sex steroid and then the dis-
covery of the leptin, as well successively of other adipocyto-
kines (adiponectin, resistin), changed completely this
traditional view. Most of the products secreted by adipose tis-
sue play a lead role in inﬂammation and immune response,
namely fat cells produce interleukin-6, tumor necrosis factor
a and many other cytokines and hormones including leptin.
This review focuses prevalently on the complex relationships
existing among leptin, inﬂammation processes and immune re-
sponse, trying to explore the paradigms that have shaped the
past decades research and what these ﬁndings forecast for
the future.2. Leptin biology overlook
Leptin is a peptide hormone that is produced predominantly
by white adipose cells [1,2]. The mature protein, that is en-
coded by the obese (ob) gene localized into human and mouse
7 and 6 chromosomes, respectively, is a 16 kDa non-glycosyl-
ated protein. Structurally, it belongs to the type I cytokine
superfamily and is characterized by a long chain four-helical
bundle structure, such as growth hormone, prolactin, IL-3,
and others. Circulating leptin levels are proportional to adi-
pose tissue mass. Thus, leptin levels can be considered as a sig-
nal to the body of its energy reserves. Although elevated leptin
levels are present in obesity, it is likely that the physiological
importance of leptin is that low levels signal starvation [3].
2.1. Modulation of leptin expression
Leptin gene expression is regulated by several factors but
mainly by food intake and hormones. For example, insulin
stimulates leptin secretion during feeding and a decrease of
insulin levels precedes a fall in leptin concentrations during
starvation in humans [4–6]. An inverse relationship between
leptin and glucocorticoids has been observed, although gluco-
corticoids may mediate a synergic action with insulin on cul-
tured adipocytes [7–9]. Leptin synthesis increases in response
to acute infection, sepsis and secretion of inﬂammatory medi-
ators as IL-1, TNF-a and LIF [10–12]. Furthermore, the
expression of this hormone is inhibited by testosterone,
whereas it is increased by ovarian sex steroids [13–15].blished by Elsevier B.V. All rights reserved.
296 M. Otero et al. / FEBS Letters 579 (2005) 295–3012.2. Leptin biological actions
Central nervous system, namely hypothalamic nuclei, is the
target where leptin exerts most of its eﬀects on energy metab-
olism. Leptin decreases food intake, increases energy expendi-
ture and decreases metabolic eﬃciency. Leptin has been shown
to inﬂuence a wide spectrum of biological functions, such as li-
pid and glucose metabolism, synthesis of glucocorticoids, insu-
lin, CD4+ T lymphocyte proliferation, cytokine secretion,
phagocytosis and synaptic transmission [16–19]. In addition,
it regulates the hypothalamic–pituitary–adrenal axis [20–22],
maturation of the reproductive system [23–26], hematopoiesis
[27,28], angiogenesis [29,30] and fetal development [31,32].2.3. Leptin receptors
Leptin receptor (Ob-R) is encoded by the diabetes (db) gene
that has been cloned from mouse choroid plexus [33,34]. The
Ob-R mRNA is alternatively spliced giving rise to six diﬀerent
spliced forms of the receptor known as Ob-Ra, Ob-Rb, Ob-Rc,
Ob-Rd, Ob-Re and Ob-Rf [35,36]. Ob-R is a member of the
class I cytokine receptor superfamily, which includes receptors
for IL-6, LIF, CNTF, OSM, G-CSF and gp 130 with predom-
inantly hematopoietic expression [37,38]. These receptors are
membrane-spanning glycoproteins. In the extracellular region,
they present ﬁbronectin type III domains and a shared
200-amino acid module, that contains four conserved cysteine
residues and the membrane proximal region WSXWS (trp-ser-
X-trp-ser) motif. The diﬀerent mRNA spliced forms encode
for Ob-R with diﬀerent length cytoplasmic domains: Ob-Rb,
also known as the long receptor isoform, has 302 cytoplasmic
residues containing the activation and signal transduction mo-
tifs; the other forms with a 34-amino acid residue cytoplasmic
domain and the soluble one (Ob-Re) lacks some or all of these
motifs. The short forms of leptin receptor are expressed in cho-
roid plexus, kidney, gonads, liver, lung and vascular endothe-
lium, where they mediate leptin transport into the brain,
degradation and clearance [39,40]. Ob-Rb is primarily ex-
pressed at high levels in the hypothalamus, especially in the
arcuate, dorsomedial, ventromedial and lateral hypothalamic
nuclei, a crucial area that secrete neuropeptides and neuro-
transmitters involved in the regulation of appetite and body
weight. Furthermore, the long isoform is expressed in murine
and human fetal liver, jejunal epithelium, pancreatic b cells,
ovarian follicular cells, vascular endothelial cells, CD34+
hematopoietic bone marrow precursors, and T lymphocytes
[17,27,29,30].2.4. Leptin receptor signal transduction: the JAK2/STAT
pathway
Ligand binding to Ob-Rb activates Janus kinases (JAK2)
and signal transducers and activators of transcription (STAT)
proteins as occurs with the other members of the class I cyto-
kine receptor family [41,42]. All the four membrane-bound lep-
tin receptors contain in the cytoplasmic tail a box 1 motif,
strongly conserved within most members of this receptor fam-
ily, whereas box 2 and 3 motifs are found only in the long iso-
form. Domains 1 and 2 are involved in the interaction and
activation of JAK2 tyrosine kinase that phosphorylates and
activates members of the STAT family of transcription factors,
such as STAT1, STAT3 and STAT5. The activation of STAT3
has been observed in vivo in the hypothalamus and requires a
box 3 motif in the receptor intracellular domain [43,44]. Acti-vated JAK2 phosphorylates tyrosine residues in the intracellu-
lar domain of Ob-Rb, providing binding motifs for SHP-2 and
STAT proteins [45–47]. These transcription factors, after tyro-
sine-phosphorylation in response to JAK activation, translo-
cate to the nucleus, where they activate gene transcription.
In particular, leptin modulates the expression of STAT3-
dependent target genes in hypothalamic neurons expressing
Ob-Rb, which include c-fos, c-jun, suppressor of cytokine sig-
naling-3 and genes encoding neuropeptides such as neuropep-
tide Y, agouti-related peptide, cocaine- and amphetamine-
regulated transcript, proopiomelanocortin and thyrotropin-
releasing hormone [46].
2.5. Leptin receptor alternative signaling pathways
In vitro and in vivo studies showed that Ob-Rb stimulates
tyrosine phosphorylation of IRS-1, PI 3-kinase activity and
SHP-2-dependent ERK1/2 activation [47,48]. On the other
hand, the short form Ob-Ra, which is highly expressed in the
microvessels of the blood–brain barrier, has the capacity in vi-
tro to activate JAK2, ERK2 and to phosphorylate IRS-1 in a
leptin-dose manner, but is not able to activate STAT3 and
downstream target c-fos gene transcription. Furthermore, it
has been shown that leptin induces a marked phosphorylation
of p38 MAP kinase in human peripheral blood mononuclear
cells [49]. Very recently, Gualillo et al. [50] demonstrated that
leptin is able to induce intracellular signal transduction path-
ways alternative to JAK/STAT by inducing tyrosine phos-
phorylation of the SH(2) containing protein SHC. These
studies, carried out on a human embryonic cell line (HEK
293) transfected with the cDNA encoding for the long form
of the leptin receptor and stably expressing the receptor itself,
showed that upon tyrosine phosphorylation, SHC associated
with the adaptor protein, Grb-2. The formation of this com-
plex may directly link tyrosine phosphorylation events to
Ras activation and may be a critical step in proliferation
and/or diﬀerentiation of cells, indicating that leptin receptor,
after binding the ligand, activates several pathways for signal
transduction that might lead to mitogenic eﬀect. Very recent
data have demonstrated the critical role of speciﬁc tyrosine res-
idues conserved in the cytoplasmic domains namely those situ-
ated at positions Y985, Y1077 and Y1138 of the murine
receptor. For instance, the Y1138 residue seems likely to be
a typical STAT3 docking site and the sharp role of this residue
was further conﬁrmed by knock-in mice expressing a Y1138S
mutated receptor. This mutation induces a deep obesity in
the knocked-in mice and suggests an essential role for the
Y1138, and thus also for STAT3, in leptin-regulated energy
homeostasis. However, and intriguingly, infertility and other
defects naturally observed in the db/db mouse were not found
in the Y1138S knock-in mouse, so implying a STAT3-indepen-
dent leptin receptor signaling transduction pathway [51,52].3. Leptin: a novel immunomodulator
Several studies have demonstrated that leptin circulating lev-
els increase during infection and inﬂammation, suggesting that
leptin is part of the immune response and host defense mech-
anisms. Leptin levels are acutely increased by many acute
phase factors, such as TNF, IL-1 and IL-6, and during bacte-
rial infection, or lipopolysaccharide challenge [53]. Further-
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paw edema and carrageenan-induced pleurisy [12]. Leptin, per
se, acts on monocytes/macrophages by inducing eicosanoids
synthesis, nitric oxide and several pro-inﬂammatory cytokines
[54,55]. In addition, leptin potentiates IFN-c-induced expres-
sion of nitric oxide synthase and cyclo-oxygenase-2 in murine
macrophage J774A.1 [56]. Moreover, leptin induces chemo-
taxis of neutrophils and the release of oxygen radicals
[57,58]. Leptin also aﬀects natural killer (NK)-cell develop-
ment and activation both in vitro and in vivo [59,60]. As NK
cells express OBRb and db/db mice have a deﬁcit of NK cells
resulting from abnormal NK-cell development, it is reasonable
that leptin might inﬂuence the development/maintenance of a
normal peripheral NK-cell pool. Indeed, an important role
of OBRb in NK-cell physiology is indicated by the ability of
OBRb to inﬂuence NK-cell cytotoxicity through direct activa-
tion of signal transducer and activator of transcription 3.
Finally, it has recently been shown that leptin stimulates the
production of growth hormone by peripheral-blood mononu-
clear cells through protein kinase C (PKC)- and nitric
oxide-dependent pathways [61]. This eﬀect of leptin on the pro-
duction of growth hormone might be important in immune
homeostasis, given the fact that this cytokine-like hormone
has marked inﬂuences on immune responses by controlling
the survival and proliferation of immune cells.
Leptin has been demonstrated to also modulate adaptive im-
mune response. This is divided classically into T helper 1 and 2
immune responses on the basis of the cytokine pattern pro-
duced. T helper 1 lymphocytes produce mainly pro-inﬂamma-
tory cytokines that are necessary for macrophage activation
and cell-mediated response, whereas T helper 2 lymphocytes
secrete modulatory and anti-inﬂammatory peptides that are
important factors for the activation of B cells and basophils.
The role of leptin in adaptive immune response was recently
and extensively reviewed by La Cava and Matarese [62], and
here we brieﬂy summarize some of the aspects previously ex-
posed. Recent articles reported that leptin deﬁciency is respon-
sible for the immunosuppression and thymic atrophy observed
during acute starvation and reduced caloric intake [17]. The
impairment of the immune response is associated with a dra-
matic fall in serum leptin and is reverted by exogenous leptin
in rodents. Leptin in mice is necessary for an eﬀective cell-med-
iated immunity and the CD4+ T lymphocytes function is sub-
optimal in the absence of leptin as observed in the ob/ob mice
[17]. In addition, there are several evidences that leptin partic-
ipates in the maintenance of thymic maturation of double po-
sitive CD4+/CD8+ cells and prevents glucocorticoids-induced
apoptosis in thymocytes, since both leptin deﬁcient mice as
well as starved animals show a reduction in the thymus cortex
and exogenous leptin administration is able to restore normal
thymic function, increasing the number of CD4+/CD8+ T lym-
phocytes and reducing thymic apoptosis [63].
3.1. Leptin and autoimmune diseases
Leptin likely has an important role in autoimmune states
such as those observed in inﬂammatory bowel disease, multiple
sclerosis, type 1 diabetes and rheumatoid arthritis.
Inﬂammatory bowel disease is often associated with a
marked weight loss compared with non-aﬀected individuals.
In a speciﬁc intestinal inﬂammation model, the trinitrobenzene
sulphonic acid colitis induced rats, it has been shown that plas-
ma leptin levels were elevated, correlated with the degree ofinﬂammation, and associated with anorexia [64]. In addition,
in the acute stage of ulcerative colitis, increased serum leptin
levels have been found in adult male patients, suggesting that
leptin levels may contribute to anorexia and weight loss [65];
furthermore, in inﬂamed colonic epithelial cells, leptin is ex-
pressed and released into the intestinal lumen [66]. Very re-
cently, a key role for intestinal leptin in a immune
experimental model of mice chronic intestinal inﬂammation
has been demonstrated. Leptin actions in this model appear
to be mediated by leptin receptor transduction pathway on
Th-1 lymphocytes [67].
In experimental autoimmune encephalomyelitis, a mouse
model for multiple sclerosis, the onset of the disease is pre-
ceded by an augment of serum leptin concentrations [68].
Noteworthy, acute starvation, which reduces serum leptin lev-
els, delays disease onset and attenuates the symptoms. In addi-
tion, leptin-deﬁcient ob/ob mice are resistant against
encephalomyelitis. This resistance is abolished by administra-
tion of leptin, which is accompanied by a switch from a Th2
to Th1 pattern of cytokine release [69].
In type 1 diabetes, the pancreatic b-cells are destroyed by im-
mune-inﬂammatory processes. The non-obese diabetic (NOD)
mouse is one of the best animal model for type 1 diabetes. In
NOD susceptible female mice, increased serum level of leptin
precedes the onset of diabetes, whereas injection of leptin
speed up the autoimmune destruction of the pancreatic b-cells
and increases the IFN-c production in peripheral T-cells, argu-
ing that leptin promotes the development of type 1 diabetes
through Th1 responses [70].3.2. Leptin and rheumatoid arthritis
Leptin likely plays a major role in the pathogenesis of rheu-
matoid arthritis. In experimental antigen-induced arthritis,
both ob/ob and db/db mice develop less severe arthritis in com-
parison with wild type mice and display decreased interleukin-
1b and tumor necrosis factor-a in the knee synovial ﬂuid. In
addition, ob/ob mice display a decreased antigen-speciﬁc T-cell
proliferative response, with a lower interferon-c and a higher
IL-10 secretion [71]. The increased leptin production in RA pa-
tients further argues for a role of leptin in the pathogenesis of
RA. In patients with rheumatoid arthritis, it was reported that
fasting leads to an improvement of diﬀerent clinical and bio-
logical measures of disease activity, which was associated with
a marked decrease in serum leptin and a shift towards Th2
cytokine production [72]. These features, resembling those pre-
viously depicted in ob/ob mice, suggest that leptin may also
inﬂuence the inﬂammatory mechanisms of arthritis in humans
through the induction of Th1 responses.
Bokarewa et al. [73] reported increased plasma levels of lep-
tin in 76 patients with RA as compared with healthy controls.
In this work, it has also been observed that circulating plasma
concentrations of leptin were signiﬁcantly higher than leptin
levels in matched synovial ﬂuid samples and that the diﬀerence
between plasma and synovial ﬂuid was particularly pro-
nounced in non-erosive arthritis. So, these authors concluded
that intra-articular leptin may exert a protective eﬀect against
the destructive course of RA. Unfortunately, these data were
aﬀected by several problems that signiﬁcantly limit the inter-
pretation of their results [74].
At joint cartilage level, it has been demonstrated that chon-
drocytes express leptin and its cognate long form receptor
Fig. 1. Schematic illustration of the pleiotropic eﬀects of leptin at central level and in the periphery with particular attention to immune system and
inﬂammatory response in chondrocytes.
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fect of leptin on chondrocytes. Actually, leptin has a synergis-
tic eﬀect with IFN-c on nitric oxide synthase type II induction
in cultured chondrocytes [77]. Nitric oxide is a gaseous media-
tor, induced by a wide range of pro-inﬂammatory cytokines,
that causes most of the inﬂammatory alterations on cartilage
including chondrocytes phenotype loss, chondrocytes apopto-
sis and metalloproteases activation [78]. Therefore, leptin
likely acts a typical pro-inﬂammatory cytokine because of its
synergistic action with IFN-c on nitric oxide synthase type II
(Fig. 1).
Even if some data suggested a protective eﬀect of leptin in
chondrocytes [79], our results pointed on a detrimental eﬀect
on chondrocytes. To further conﬁrm a pro-inﬂammatory role
of leptin in cartilage, recent data obtained by our group re-
ported a synergistic eﬀect of leptin also with IL-1, probably
the most relevant cytokine playing in inﬂammatory diseases
such as osteoarthritis, on nitric oxide synthase type II synthesis
and activity in cultured chondrocytes by a signaling pathway
that involves JAK2 kinase, PI-3 kinase, MEK-1 and p38 ki-
nase [80]. These data conﬁrm that leptin is a pro-inﬂammatory
cytokine, and suggests that it could be the link between obesity
and inﬂammatory conditions, particularly those related with
alterations of cartilage metabolism.4. Concluding remarks and future perspectives
Since the discovery of leptin in 1994, the volume of literature
on leptin biology is impressive. Although an endless series of
relevant works have been carried out in the last decade to clar-
ify the biologic role of leptin, many cellular and molecular as-
pects of this adipokine in immune response and inﬂammatory
processes remain elusive. Leptin interactions with inﬂamma-tion and immune system are similar to a dynamic puzzle, but
where they ﬁt the puzzle is still unclear.
Nonetheless, particularly because of the close link between
nutritional status and immunity and leptin modulation by
food intake, this adipokine could be considered as a new po-
tential immunological therapeutic target in conditions where
leptin is thought to promote inﬂammatory or autoimmune dis-
eases. For instance, one could suggest that the stress responses
of acute starvation could be beneﬁcial in some autoimmune
conditions in which leptin promotes chronic inﬂammation.
However, the hypoleptinaemia during starvation would be a
potential mechanism for increased susceptibility to infection
and decreased T cell response secondary to malnutrition.
One potential strategy, that at ﬁrst sight appears viable to
counteract undesired leptin action in inﬂammatory and auto-
immune diseases, is the possibility to use a soluble receptor,
able to assure high aﬃnity leptin binding thereby controlling
the amount of bioavailable leptin. A comparable strategy
was recently introduced in the clinical practice to antagonize
the detrimental eﬀects of tumor necrosis factor in rheumatoid
arthritis. Other potential therapeutic interventions to antago-
nize leptin can be achieved by the use of monoclonal human-
ized antibodies or by leptin mutants with antagonistic
properties which should be able to bind the leptin receptor
complex without activating it [81]. However, due to the fact
that leptin investigations were initially focused on weight reg-
ulation, and considering that major leptin eﬀect on food intake
and energy expenditure occurs at the hypothalamic level and
that all the above mentioned molecules do not cross the blood
brain barrier, only little care has been given to the development
of a protein based anti-leptin therapy. Nonetheless, based on
the recent observations supporting a major role of leptin in
immunity, and considering that most of the eﬀects on the im-
mune system and inﬂammatory response are mediated directly
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that the development of such a molecule should be boosted as
a promising therapeutic intervention for inﬂammatory degen-
erative diseases such as rheumatoid arthritis, osteoarthritis
and others.
In conclusion, there is an increasing evidence that leptin, be-
sides its central eﬀects on food intake and energy expenditure,
is involved (per se or by synergistic action with other cyto-
kines) in the pathogenesis of inﬂammatory and autoimmune
diseases. The evidence that leptin signaling deﬁciency impairs
humoral and cellular immune responses, and attenuates exper-
imental inﬂammation models, supports the notions that a
strategy focused on the block of leptin activity on peripheral
cells might have intriguing therapeutic beneﬁts.
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